A method of improving cognition in a patient with Down syndrome, which entails intranasally administering one or more 2-ADR agonists or pharmaceutically-acceptable salts of either or both to the patient in an amount and with a frequency effective to improve cognition of the patient as measured contextual learning tests.

The present invention relates to a ready-to-administer parenteral dosage form of norepinephrine which comprises an aqueous solution of norepinephrine, having an anti-oxidant which is not a sulfite anti-oxidant, wherein the dosage form is stable at room temperature for prolonged period of time.

A soil enhancement system and method is configured to eradicate undesirable plant-life while providing enhancing nutrients to the soil. The method includes applying non-toxic acid-based solution to one or more invasive plants in a soil. The method also includes dehydrating, by the non-toxic acid-based solution, the one or more invasive plants by disturbing a water-retaining capacity of a number of cells of the one or more invasive plants. The method further includes generating one or more beneficial nutrients; and delivering the one or more beneficial nutrients to the soil.

A soil enhancement system and method is configured to eradicate undesirable plant-life while providing enhancing nutrients to the soil. The method includes applying non-toxic acid-based solution to one or more invasive plants in a soil. The method also includes dehydrating, by the non-toxic acid-based solution, the one or more invasive plants by disturbing a water-retaining capacity of a number of cells of the one or more invasive plants. The method further includes generating one or more beneficial nutrients; and delivering the one or more beneficial nutrients to the soil.

Provided is a polymer material having effective antibacterial properties and having bio adaptability in which cytotoxicity, especially low hemolysis, when used in contact with in vivo tissue and blood is suppressed so as to be low. The polymer is characterized by comprising a main chain and a side chain portion which is linked to the main chain via a linker and which contains at least a structure specified by the following (A) and (B). (A) A structure containing a cationic group and (B) a structure in which expression of bio adaptability is expected.

Provided is a polymer material having effective antibacterial properties and having bio adaptability in which cytotoxicity, especially low hemolysis, when used in contact with in vivo tissue and blood is suppressed so as to be low. The polymer is characterized by comprising a main chain and a side chain portion which is linked to the main chain via a linker and which contains at least a structure specified by the following (A) and (B). (A) A structure containing a cationic group and (B) a structure in which expression of bio adaptability is expected.

Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.

This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol.

The present invention relates to the use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment of bacteria including those presenting multiple drug resistance (MDR), in particular as efflux pump inhibitors. It also relates to novel polyaminoisoprenyl derivatives, compositions comprising the same, process for preparing the same, and use thereof in antibiotic or antiseptic treatment.

An antibacterial agent includes a block isocyanate. The block isocyanate includes a capped residue (A) of a polyisocyanate, an antibacterial-non-block capping group (B), and a non-antibacterial-block capping group (C). The capped residue (A) of the polyisocyanate is formed by capping an isocyanate group of the polyisocyanate having a plurality of isocyanate groups. The antibacterial-non-block capping group (B) is formed by non-reproducibly capping at least a portion of the plurality of isocyanate groups. The non-antibacterial-block capping group (C) is formed by reproducibly capping at least a portion of the plurality of isocyanate groups. The antibacterial-non-block capping group (B) includes a quaternary ammonium group.